Acute Mountain Sickness clinical trials at UCSF
1 research study open to eligible people
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
open to eligible people ages 18-55
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
San Francisco, California
Our lead scientists for Acute Mountain Sickness research studies include Jeffrey W Sall, PhD, MD.